Jardiance Pediatric (Under 12): Developmental Impact

FDA Approval Status for Children Under 12

Empagliflozin received FDA approval for pediatric patients aged 10 years and older with type 2 diabetes in December 2023, based on a supplemental New Drug Application supported by the DINAMO trial and pharmacokinetic bridging data. Children younger than 10 years old have no approved indication, and the prescribing information explicitly excludes this population.

What the 2023 Label Extension Actually Covers

The December 2023 label expansion covers type 2 diabetes mellitus in patients 10 years and older, at a starting dose of 10 mg once daily, with uptitration to 25 mg permitted based on tolerability and glycemic response. The FDA label does not authorize any use in children under 10, nor does it address type 1 diabetes or other off-label indications in any pediatric age group.

Children aged 10 and 11 sit at the boundary of this approval. For a child who turned 10 just weeks before a prescription is written, the clinical picture resembles that of a 9-year-old far more than it resembles the adolescent body on which most pediatric metabolic data were gathered.

Children Under 10: No Approval, Limited Data

No completed randomized controlled trial has evaluated empagliflozin safety or efficacy as a primary endpoint in children younger than 10 years. The DINAMO trial enrolled patients aged 10 to 17 years with type 2 diabetes. Extrapolating those results downward to a 7- or 8-year-old introduces pharmacokinetic uncertainty, developmental variability, and an entirely different risk-benefit calculus.

The American Diabetes Association's 2024 Standards of Care state that metformin and insulin remain the primary pharmacologic options for children under 10 with type 2 diabetes, with no recommendation supporting SGLT2 inhibitor use in this cohort.

How SGLT2 Inhibitors Work and Why That Mechanism Concerns Pediatricians

Empagliflozin blocks sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, causing the kidney to excrete glucose in urine rather than reabsorb it. In adults with established type 2 diabetes, that glycosuria translates to HbA1c reductions of approximately 0.5 to 0.7 percentage points and modest weight loss of 2 to 3 kg at standard doses [1].

In a developing child, the same mechanism operates in a body that is simultaneously building bone, brain, and lean tissue, and that depends heavily on consistent glucose availability and intact renal function.

Glycosuric Caloric Loss During Active Growth

Children under 12 are often in a period of accelerated linear growth. A child excreting 60 to 80 grams of glucose daily (a realistic load on empagliflozin 10 mg) loses roughly 240 to 320 kilocalories per day through urine. In an adult pursuing weight loss, that is a desirable effect. In a 7-year-old growing 6 to 7 cm per year, chronic caloric diversion away from anabolic growth pathways is a legitimate concern.

No long-term pediatric growth data exist for empagliflozin. Height-velocity data from the DINAMO trial were not a prespecified primary or secondary endpoint, which means clinicians lack controlled evidence on whether SGLT2-induced glycosuria affects stature in children aged 10 to 17, let alone those younger.

Renal Maturation and Tubular Function

Adult SGLT2 inhibitor dosing assumes a fully mature proximal tubule. In children under 10, renal tubular transport capacity is still developing. Glomerular filtration rate (GFR) normalized to body surface area reaches adult values around age 2, but tubular secretory and reabsorptive pathways continue maturing through early adolescence [2].

The clinical implication: standard dose-exposure relationships for empagliflozin, derived from adult and older-pediatric pharmacokinetic modeling, may not reliably predict drug exposure in a child whose tubular function differs qualitatively, not just quantitatively, from an adult's.

Bone Development and Fracture Risk

Bone safety is one of the clearest areas of concern when considering SGLT2 inhibitors in children under 12. Peak bone mass accrual occurs primarily between ages 9 and 18 years, with roughly 40% of total lifetime bone mineral density deposited during this window [3].

SGLT2 Inhibitors and Bone Mineral Density

Adult data from the FDA's 2015 safety communication on canagliflozin identified a signal for decreased bone mineral density (BMD) and increased fracture risk with SGLT2 inhibitor use [4]. The proposed mechanism involves increased phosphate reabsorption causing transient changes in FGF-23 and parathyroid hormone, both of which affect bone turnover.

Empagliflozin's prescribing information for adults does not carry a fracture warning as prominent as canagliflozin's, but the class-level biological mechanism is shared. In a child aged 8 to 11 years, even modest suppression of bone accrual during the critical pre-pubertal window could reduce peak bone mass and raise lifetime fracture risk in a way that no short-term clinical trial would detect.

No Pediatric BMD Trial Data for Empagliflozin

As of the 2025 publication date of this article, no published trial has prospectively measured dual-energy X-ray absorptiometry (DXA) outcomes in children treated with empagliflozin. This is not a reassuring absence of signal. It is a genuine data gap. Prescribers choosing to use empagliflozin in a child under 12 for any indication are doing so without bone safety data specific to that age group.

The HealthRX pediatric SGLT2 risk-stratification framework (reviewed by our medical team) flags three conditions as hard stops before initiating empagliflozin in any patient under 12: (1) baseline DXA Z-score below minus 2.0 for age and sex, (2) estimated GFR below 60 mL/min/1.73 m2, and (3) evidence of caloric insufficiency or failure to maintain expected height velocity over two consecutive 6-month intervals.

Genital Mycotic and Urinary Tract Infections in Young Children

Glycosuria creates a glucose-rich urogenital environment that promotes fungal and bacterial overgrowth. In adults, genital mycotic infections are one of the most common adverse effects of SGLT2 inhibitors, affecting roughly 10% of women and 4% of men in clinical trials [5].

Why Children Face Disproportionate Risk

Children under 12 have immature local immune defenses in the genitourinary tract. Girls who are pre-estrogenic lack the estrogen-driven changes in vaginal flora that provide some protection in post-pubertal women. Boys who are uncircumcised face a particularly elevated risk of balanoposthitis, a condition associated with SGLT2 inhibitor use in both children and adults.

In the DINAMO trial, the rate of genital mycotic infections in patients aged 10 to 17 treated with empagliflozin was notably higher than in adult trial populations, consistent with a pattern seen across the SGLT2 inhibitor class in younger patients [6].

A child under 10 would likely show an even more pronounced infection risk, though controlled data do not exist to quantify it.

Urinary Tract Infections

Recurrent urinary tract infections (UTIs) in children can lead to renal scarring, particularly in those with vesicoureteral reflux or other anatomic variants that are not always identified before a diabetes diagnosis. The glycosuric environment created by empagliflozin could increase UTI frequency in a population already at risk for renal sequelae from recurrent infections [7].

Diabetic Ketoacidosis Risk in Young Patients

Euglycemic diabetic ketoacidosis (DKA) is a well-documented risk with SGLT2 inhibitors. The mechanism involves reduced insulin secretion stimulus (from lower glucose), increased glucagon secretion, and accelerated lipolysis, all of which drive ketone production even when blood glucose remains below 250 mg/dL.

Type 1 Diabetes Overlap in Children

In children under 12, a new diagnosis labeled as type 2 diabetes may be misclassified. Latent autoimmune diabetes of childhood (LADC) and slowly progressive type 1 diabetes can present in overweight children in ways that mimic type 2 phenotypes. An SGLT2 inhibitor given to a child who actually has autoimmune-mediated insulin deficiency carries a substantially elevated DKA risk.

The FDA's 2015 safety communication on euglycemic DKA with SGLT2 inhibitors [8] was issued for adult patients. Children with any degree of underlying beta-cell autoimmunity are likely at higher risk, and type 1 antibody testing (GAD65, IA-2, ZnT8) before initiating any non-insulin agent in a pediatric patient under 12 is standard practice in many academic pediatric endocrinology centers.

Sick-Day Risk in Young Children

Children under 12 get sick more often than adults. Each intercurrent illness, especially one involving vomiting or reduced oral intake, significantly raises the risk of SGLT2-associated DKA. Young children may also be less able to communicate prodromal DKA symptoms such as nausea, abdominal pain, or deep breathing. Parents may not recognize euglycemic DKA, given that glucose meters may read in an apparently acceptable range while ketones are rising to dangerous levels.

Growth Hormone and Metabolic Axis Considerations

Childhood is a period of active growth hormone (GH) and insulin-like growth factor 1 (IGF-1) axis activity. Insulin itself plays a permissive role in IGF-1 signaling, particularly at the liver. SGLT2 inhibitors reduce insulin secretory demand by lowering postprandial glucose. In adults, this is a benefit. In a growing child, any reduction in insulin's anabolic signaling role is worth monitoring carefully.

Pubertal Timing

Pre-pubescent children (Tanner stage 1 or 2) have different hormonal milieu than adolescents. GnRH pulsatility, adrenal androgen production, and the insulin-IGF-1 axis are all in transition during the years between 8 and 12. Whether SGLT2 inhibition at this stage could alter pubertal timing is genuinely unknown. No trial has evaluated Tanner staging progression as an outcome in empagliflozin-treated children.

One 2022 review in the Journal of Clinical Endocrinology and Metabolism noted that metabolic interventions altering insulin sensitivity during early puberty carry theoretical risks for GnRH pulse modulation, though causation has not been established for any specific drug in this class [9].

Weight and Body Composition

The modest weight reduction seen with empagliflozin in adolescents (approximately 1 to 2 kg over 26 weeks in DINAMO) may represent primarily fluid loss and glycosuric calorie loss rather than adipose tissue reduction. In a child who is not overweight, this fluid shift could affect blood pressure regulation, particularly during hot weather, exercise, or illness.

Dehydration in children progresses more quickly than in adults due to higher surface-area-to-volume ratios. Volume depletion events that are mild inconveniences in adults can become clinically significant faster in a 25-kg child.

What Happens When Empagliflozin Is Used Off-Label Under Age 10

Off-label prescribing in children is common and sometimes clinically necessary. However, off-label use should be grounded in pharmacokinetic bridging data, biological plausibility, and a favorable risk-benefit assessment. For empagliflozin in children under 10, none of those three conditions is met with current evidence.

Pharmacokinetic Gaps

The pharmacokinetic models used to support the 10-year-and-older label extension were built on data from patients aged 10 to 17. Applying those models to a 7- or 8-year-old introduces error at every level: body weight scaling, renal tubular capacity, hepatic CYP metabolism (UGT1A3 and UGT2B7 activity matures through early childhood), and protein binding.

A 2020 paper in Clinical Pharmacokinetics examining SGLT2 inhibitor pediatric pharmacokinetics found that weight-normalized clearance in younger children differs substantially from older children, and that dose extrapolation from adolescent data to children under 10 introduces uncertainty intervals too wide for confident dosing [10].

Monitoring Requirements If Off-Label Use Proceeds

If a pediatric endocrinologist makes the rare clinical judgment that empagliflozin is appropriate for a child under 10 with type 2 diabetes refractory to metformin and insulin optimization, the minimum monitoring standards should include: fasting lipids and renal function every 3 months, urine ketone measurement at every sick visit, baseline and annual DXA scanning, Tanner staging at each visit, and height-velocity tracking plotted against WHO reference growth charts.

Even with that monitoring in place, families should be counseled explicitly that the evidence base for this decision is thin, the potential for undetected developmental harm over a 5- to 10-year exposure period is real, and dose interruption at the first sign of growth faltering, recurrent infection, or bone pain is appropriate.

Guidelines and Clinical Recommendations

ADA 2024 Position

The American Diabetes Association's 2024 Standards of Medical Care in Diabetes state: "In youth with type 2 diabetes aged 10 years or older, empagliflozin may be used as an adjunct to diet and exercise." The guidance explicitly limits this recommendation to patients 10 years old and above, with no recommendation for younger children [11].

Endocrine Society Guidance

The Endocrine Society's 2023 clinical practice guideline on pediatric obesity-related comorbidities advises against initiating any agent with an incomplete pediatric safety database in children under 10 outside of an institutional review board-approved research protocol. That guidance applies directly to SGLT2 inhibitors in this age group [12].

Practical Clinical Takeaway

For children under 10 with type 2 diabetes, metformin (FDA-approved down to age 10, and used off-label in younger children with extensive real-world data) and insulin remain the only agents with a pharmacokinetic and safety database sufficient to support clinical confidence. For children aged 10 and 11, empagliflozin is technically on-label, but the youngest end of that range should be managed by a board-certified pediatric endocrinologist, not a general practitioner, given the developmental considerations outlined here.

Children in this age range prescribed empagliflozin should receive the lowest approved starting dose of 10 mg once daily, with reassessment of height velocity, renal function, and bone health at 6-month intervals.